Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthesis method for nanoparticles capable of treating autoimmune hepatitis

An autoimmune, nanoparticle technology, used in cyclic peptide components, drug combinations, pharmaceutical formulations, etc., can solve problems such as side effects and unsatisfactory efficacy, and achieve good biocompatibility, good encapsulation and film formation. the effect of performance

Inactive Publication Date: 2020-08-11
TIANJIN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the efficacy of this therapy is sometimes unsatisfactory, and continued use can cause severe side effects, highlighting the need to explore a highly effective, safe and better treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method for nanoparticles capable of treating autoimmune hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 1) Weigh 10 mg of PLGA material, add 20 ml of dichloromethane and dissolve it ultrasonically to obtain a PLGA organic solution with a concentration of 0.5 mg / ml;

[0023] 2) Weigh 10 mg of PEG material, add 20 ml of water and ultrasonically dissolve to obtain a PEG aqueous solution with a concentration of 0.5 mg / ml;

[0024] 3) Weighing 20 mg of cyclosporin material, adding 20 ml of dichloromethane and ultrasonically dissolving to obtain an organic solution of cyclosporin with a concentration of 1 mg / ml;

[0025] 4) Synthesis of HIV-Vpu protein@cyclosporin@PEG-PLGA nanoparticles by thin film hydration method.

[0026] (1) Place the one-mouth bottle containing 2ml of PLGA solution on the ultrasonic breaker, start ultrasonication, set the time to 12min, the temperature to 0°C, and the ultrasonic frequency to 4s, 2s;

[0027] (2) Add 100uL of cyclosporine solution and 2ml of PEG aqueous solution drop by drop while ultrasonicating, and continue ultrasonicating until comple...

Embodiment 2

[0031] 1) Weigh 5 mg of PLGA material, add 20 ml of dichloromethane and dissolve it ultrasonically to obtain a PLGA organic solution with a concentration of 0.25 mg / ml;

[0032] 2) Weigh 5 mg of PEG material, add 20 ml of water and ultrasonically dissolve to obtain a PEG aqueous solution with a concentration of 0.25 mg / ml;

[0033] 3) Weigh 10 mg of cyclosporine material, add 20 ml of dichloromethane and dissolve it ultrasonically to obtain an organic solution of cyclosporine with a concentration of 0.5 mg / ml;

[0034] 4) Synthesis of HIV-Vpu protein@cyclosporin@PEG-PLGA nanoparticles by thin film hydration method.

[0035] (1) Place the one-mouth bottle containing 2ml of PLGA solution on the ultrasonic breaker, start ultrasonication, set the time to 12min, the temperature to 0°C, and the ultrasonic frequency to 4s, 2s;

[0036] (2) Add 100uL of cyclosporine solution and 2ml of PEG aqueous solution drop by drop while ultrasonicating, and continue ultrasonicating until complet...

Embodiment 3

[0040] 1) Weigh 20 mg of PLGA material, add 20 ml of dichloromethane and dissolve it ultrasonically to obtain a PLGA organic solution with a concentration of 1 mg / ml;

[0041] 2) Weigh 20mg of PEG material, add 20ml of water and ultrasonically dissolve to obtain a PEG aqueous solution with a concentration of 1mg / ml;

[0042] 3) Weigh 30 mg of cyclosporin material, add 20 ml of dichloromethane and dissolve it ultrasonically to obtain an organic solution of cyclosporine with a concentration of 1.5 mg / ml;

[0043] 4) Synthesis of HIV-Vpu protein@cyclosporin@PEG-PLGA nanoparticles by thin film hydration method.

[0044] (1) Place the one-mouth bottle containing 2ml of PLGA solution on the ultrasonic breaker, start ultrasonication, set the time to 12min, the temperature to 0°C, and the ultrasonic frequency to 4s, 2s;

[0045] (2) Add 100uL of cyclosporine solution and 2ml of PEG aqueous solution drop by drop while ultrasonicating, and continue ultrasonicating until completely mixe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a synthesis method for nanoparticles capable of treating autoimmune hepatitis. The synthesis method comprises the following main steps of: 1) preparing a PEG (polyethylene glycol) aqueous solution; 2) preparing a PLGA (poly (lactic-co-glycolic acid)) organic solution; and 3) through a thin film hydration method, synthesizing cyclosporine @ HIV-Vpu protein nanoparticles. Anaccessory protein U (Vpu) can inhibit the activation of a transcription factor which is called NF-kB, reduces the generation of a cell factor which performs a key function in immune reaction, and inhibits an organism immune function. The cyclosporine is a microbial metabolism production, regulates the growth and the differentiation of cells, participates in inflammatory reaction and immune reaction and is an accepted inflammation and immunosuppression factor at present. PLGA-PEG is nontoxic, has good biocompatibility and has good sacculation and film formation performance.

Description

technical field [0001] The present invention relates to the technical field of nanoparticle synthesis, in particular to a method for synthesizing HIV-Vpu protein@cyclosporin@PEG-PLGA nano preparation by encapsulating HIV-Vpu protein and cyclosporine with PLGA-PEG. Background technique [0002] Autoimmune hepatitis involves complex pathological mechanisms. Autoimmune diseases refer to the loss of immune tolerance to self-antigens, the production of tissue self-antigen antibodies, and the occurrence of autoimmune phenomena. Nonspecific immunosuppressive or anti-inflammatory drugs, such as glucocorticoids (GCs), cyclophosphamide, and methotrexate, are commonly used in autoimmune diseases. However, the efficacy of this therapy is sometimes unsatisfactory, and continuous use can cause serious side effects, which highlights the need to explore a highly effective, safe and better treatment. HIV produces a variety of proteins that play a role in suppressing the immune response. Am...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/51A61K47/34A61K38/16A61K38/13A61P1/16A61P31/14A61P31/20A61P37/06
CPCA61K9/5153A61K38/162A61K38/13A61P1/16A61P31/14A61P31/20A61P37/06
Inventor 郑斌彭文畅明东甘霖
Owner TIANJIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com